PharmaPoint: Parkinson’s Disease – Global Drug Forecast and Market Analysis to 2022

Pages: 320 Published: June 01, 2015 Report Code: GDHC011EPIDR

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. It is expected that the prevalence of Parkinson’s disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Scope

Overview of Parkinson’s disease, including etiology, pathophysiology, motor and non-motor symptoms, and quality of life.

Annualized Parkinson’s disease market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD market.

Pipeline analysis: comprehensive data split across different Phases and emerging trends, specifically Biotie’s tozadenant, Acorda’s CVT-301, Bial’s opicapone, and Intec’s CD/LD-GR, and well as the recently launched drugs: Newron/Zambon’s Xadago and Impax’s Rytary (IPX066).

Analysis of the current and future market competition in the global Parkinson’s disease market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?

With the recent launch of Xadago and Rytary and an additional four drugs in the late-stage pipeline, which products are forecast to generate the highest sales over 2012-2022?

What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?

An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?

What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?

Key Players

Merck
Roche
AbbVie
UCB
GlaxoSmithKline
Novartis
Orion
Newron
Impax
Lundbeck

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Prognosis

3.1.4Quality of Life

3.2Symptoms

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.2.1The risk of developing Parkinson’s disease progressively increases with age

4.2.2The risk for Parkinson’s disease is increased with Parkinson’s disease–causing mutations

4.2.3Men are

1.5 times more likely to develop Parkinson’s disease than women, though the difference may be the result of varying exposures to environmental factors

4.2.4Chemicals, along with exposure to other environmental factors, increase the risk of developing Parkinson’s disease

4.2.538% of Parkinson’s disease cases experienced depression and/or anxiety compared with only 8% of controls

4.3Global and Historical Trends

4.3.1US

4.3.25EU

4.3.3Japan

4.3.4Brazil

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods

4.5Epidemiological Forecast of Parkinson’s Disease (2012–2022)

4.5.1Prevalent Cases of Parkinson’s Disease

4.5.2Age-Specific Prevalent Cases of Parkinson’s Disease

4.5.3Sex-Specific Prevalent Cases of Parkinson’s Disease

4.5.4Age-Standardized Prevalence of Parkinson’s Disease

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Overview

5.1.1Diagnosis – The UK Brain Bank Criteria

5.1.2Treatment Guidelines and Leading Prescribed Drugs

5.2Treatment Synopsis

5.2.1Dopaminergic Therapy Classes

5.2.2Treatment of Parkinson’s Disease by Stage

5.2.3Other Treatment Options

5.3Parkinson’s Disease Assessment Scales

5.3.1Unified Parkinson’s Disease Rating Scale (UPDRS)

5.3.2Hoehn and Yahr Clinical Staging

5.3.3Other Clinical Assessments

5.4Diagnosis and Treatment of Parkinson’s Disease by Country

5.4.1US

5.4.2France

5.4.3Germany

5.4.4Italy

5.4.5Spain

5.4.6UK

5.4.7Japan

5.4.8Brazil

6Competitive Assessment

6.1Overview

6.2Strategic Competitor Assessment

6.3Product Profiles – Levodopa Combination Therapy

6.3.1Madopar (levodopa/benserazide)

6.3.2Sinemet (carbidopa/levodopa)

6.3.3Rytary

6.3.4Duodopa (carbidopa/levodopa intestinal gel)

6.4Product Profiles – COMT Inhibitors

6.4.1Stalevo/Comtan (entacapone)

6.5Dopamine Agonists

6.5.1Neupro (rotigotine transdermal patch)

6.5.2Requip/Requip XL (ropinirole)

6.5.3Apokyn (apomorphine)

6.6Product Profiles – MAO-B Inhibitors

6.6.1Azilect (rasagiline)

6.6.2Xadago (safinamide)

6.7Product Profiles – Adenosine 2A Inhibitor

6.7.1Nouriast (istradefylline)

6.8Product Profiles – Other Therapies

7Opportunity and Unmet Need

7.1Overview

7.2Treatment of Motor Complications – Dyskinesias and OFF Episodes

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Treatment of Non-Motor Symptoms and Dementia

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Neuroprotective/Disease-Modifying Agents

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Improved Drug Formulations

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

7.6Identification of Reliable Biomarkers

7.6.1Unmet Need

7.6.2Gap Analysis

7.6.3Opportunity

7.7Improved Clinical Trial Design

7.7.1Unmet Need

7.7.2Gap Analysis

7.7.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Class/Patient Population/Biomarkers/Line of Therapy

8.3Promising Drugs in Clinical Development

8.3.1Tozadenant

8.3.2CVT-301

8.3.3Opicapone

8.3.4AP – CD/LD

8.3.5Other Late-Stage Pipeline Products

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Merck

9.3.2Roche

9.3.3AbbVie

9.3.4UCB

9.3.5GlaxoSmithKline

9.3.6Novartis

9.3.7Orion

9.3.8Newron

9.3.9Impax

9.3.10Lundbeck

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.3France

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Germany

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5Italy

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

10.6Spain

10.6.1Forecast

10.6.2Key Events

10.6.3Drivers and Barriers

10.7UK

10.7.1Forecast

10.7.2Key Events

10.7.3Drivers and Barriers

10.8Japan

10.8.1Forecast

10.8.2Key Events

10.8.3Drivers and Barriers

10.9Brazil

10.9.1Forecast

10.9.2Key Events

10.9.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Parkinson’s Disease Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Compliance Assumptions

11.4.7Individual Drug Assumptions

11.4.8Generic Erosion

11.4.9Pricing of Pipeline Agents

11.5Physicians and Specialists Included in this Study

11.6About the Authors

11.6.1Author

11.6.2Epidemiologist

11.6.3Global Head of Healthcare

11.7About GlobalData

11.8Disclaimer

List of Tables

Table 1: Symptoms of Parkinson’s Disease

Table 2: Risk Factors and Comorbidities for Parkinson’s Disease

Table 3: Sources of Diagnosed Prevalence Data Used in the Epidemiology Forecast

Table 4: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, Ages =65 Years, Both Sexes, N, Select Years, 2012–2022

Table 5: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Age, N (Row %), 2012

Table 6: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Sex, N (Row %), 2012

Table 7: UK Brain Bank Diagnostic Criteria

Table 8: Diagnosis and Treatment Guidelines for Parkinson’s Disease

Table 9: Most Prescribed Drugs for Parkinson’s Disease by Class in the Global Markets, 2014

Table 10: Dopaminergic Therapy in Parkinson’s Disease

Table 11: UPDRS Clinical Assessment of Disease Severity

Table 12: Parkinson’s Disease Assessment Scales Used in Clinical Trials

Table 13: Parkinson’s Disease, Country Profile – US

Table 14: Parkinson’s Disease, Country Profile – France

Table 15: Parkinson’s Disease, Country Profile – Germany

Table 16: Parkinson’s Disease, Country Profile – Italy

Table 17: Parkinson’s Disease, Country Profile – Spain

Table 18: Parkinson’s Disease, Country Profile – UK

Table 19: Parkinson’s Disease, Country Profile – Japan

Table 20: Parkinson’s Disease, Country Profile – Brazil

Table 21: Treatment of Motor Symptoms in Parkinson’s Disease

Table 22: Leading Treatments for Parkinson’s Disease, 2014

Table 23: Product Profile – Madopar

Table 24: Madopar SWOT Analysis, 2014

Table 25: Global Sales Forecasts ($m) for Madopar, 2012–2022

Table 26: Global Sales Forecasts ($m) for Madopar CR, 2012–2022

Table 27: Product Profile – Sinemet

Table 28: Sinemet SWOT Analysis, 2014

Table 29: Global Sales Forecasts ($m) for Sinemet, 2012–2022

Table 30: Global Sales Forecasts ($m) for Sinemet CR, 2012–2022

Table 31: Product Profile – Rytary

Table 32: Rytary SWOT Analysis, 2014

Table 33: Global Sales Forecasts ($m) for Rytary, 2012–2022

Table 34: Product Profile – Duodopa

Table 35: Duodopa SWOT Analysis, 2014

Table 36: Global Sales Forecasts ($m) for Duodopa, 2012–2022

Table 37: Product Profile – Stalevo

Table 38: Product Profile – Comtan

Table 39: Stalevo/Comtan SWOT Analysis, 2014

Table 40: Global Sales Forecasts ($m) for Stalevo/Comtan, 2012–2022

Table 41: Product Profile – Neupro

Table 42: Neupro SWOT Analysis, 2014

Table 43: Global Sales Forecasts ($m) for Neupro, 2012–2022

Table 44: Product Profile – Requip/Requip XL

Table 45: Requip/Requip XL SWOT Analysis, 2014

Table 46: Global Sales Forecasts ($m) for Requip/Requip XL, 2012–2022

Table 47: Product Profile – Apokyn

Table 48: Apokyn SWOT Analysis, 2014

Table 49: Global Sales Forecasts ($m) for Apokyn Continuous Infusion, 2012–2022

Table 50: Global Sales Forecasts ($m) for Apokyn Pen, 2012–2022

Table 51: Product Profile – Azilect

Table 52: Azilect SWOT Analysis, 2014

Table 53: Global Sales Forecasts ($m) for Azilect, 2012–2022

Table 54: Product Profile – Xadago

Table 55: Summary of Relevant Clinical Trials for Xadago

Table 56: Xadago SWOT Analysis, 2014

Table 57: Global Sales Forecasts ($m) for Xadago, 2012–2022

Table 58: Product Profile – Nouriast

Table 59: Nouriast SWOT Analysis, 2014

Table 60: Global Sales Forecasts ($m) for Nouriast, 2012–2022

Table 61: Summary of Alternative Parkinson’s Disease Therapies

Table 62: Unmet Need and Opportunity in Parkinson’s Disease

Table 63: Dyskinesia Pipeline, 2014

Table 64: Dementia Pipeline, 2014

Table 65: Parkinson’s Disease-Modifying Therapeutics Pipeline, 2014

Table 66: Product Profile – Tozadenant

Table 67: Tozadenant SWOT Analysis, 2014

Table 68: Global Sales Forecasts ($m) for Tozadenant, 2012–2022

Table 69: Product Profile – CVT-301

Table 70: CVT-301 SWOT Analysis, 2014

Table 71: Global Sales Forecasts ($m) for CVT-301, 2012–2022

Table 72: Product Profile – Opicapone

Table 73: Opicapone SWOT Analysis, 2014

Table 74: Global Sales Forecasts ($m) for Opicapone, 2012–2022

Table 75: Product Profile – AP – CD/LD

Table 76: Summary of Relevant Clinical Trials for AP – CD/LD

Table 77: AP – CD/LD SWOT Analysis, 2014

Table 78: Late-Stage Pipeline, 2015

Table 79: Key Companies in the Parkinson’s Market, 2015

Table 80: Merck’s Parkinson’s Disease Portfolio Assessment, 2014

Table 81: Merck’s PD SWOT Analysis, 2014

Table 82: Roche’s Parkinson’s Disease Portfolio Assessment, 2014

Table 83: Roche’s PD SWOT Analysis, 2014

Table 84: AbbVie’s Parkinson’s Disease Portfolio Assessment, 2014

Table 85: AbbVie’s PD SWOT Analysis, 2014

Table 86: UCB’s Parkinson’s Disease Portfolio Assessment, 2014

Table 87: UCB’s PD SWOT Analysis, 2014

Table 88: GSK’s Parkinson’s Disease Portfolio Assessment, 2014

Table 89: GSK’s PD SWOT Analysis, 2014

Table 90: Novartis’ Parkinson’s Disease Portfolio Assessment, 2014

Table 91: Novartis’ PD SWOT Analysis, 2014

Table 92: Orion’s Parkinson’s Disease Portfolio Assessment, 2014

Table 93: Orion’s PD SWOT Analysis, 2014

Table 94: Newron’s Parkinson’s Disease Portfolio Assessment, 2014

Table 95: Newron’s PD SWOT Analysis, 2014

Table 96: Impax’s Parkinson’s Disease Portfolio Assessment, 2014

Table 97: Impax’s PD SWOT Analysis, 2014

Table 98: Lundbeck’s Disease/Therapy Portfolio Assessment, 2014

Table 99: Lundbeck’s SWOT Analysis, 2014

Table 100: Global Sales Forecasts ($m) for Parkinson’s Disease, 2012–2022

Table 101: Parkinson’s Disease Market – Drivers and Barriers, 2012–2022

Table 102: Sales Forecasts ($m) for Parkinson’s Disease in the US, 2012–2022

Table 103: Key Events Impacting Sales for Parkinson’s Disease in the US, 2012–2022

Table 104: Parkinson’s Disease Market in the US – Drivers and Barriers, 2012–2022

Table 105: Sales Forecasts ($m) for Parkinson’s Disease in France, 2012–2022

Table 106: Key Events Impacting Sales for Parkinson’s Disease in France, 2012–2022

Table 107: Parkinson’s Disease Market in France – Drivers and Barriers, 2012–2022

Table 108: Sales Forecasts ($m) for Parkinson’s Disease in Germany, 2012–2022

Table 109: Key Events Impacting Sales for Parkinson’s Disease in Germany, 2012–2022

Table 110: Parkinson’s Disease Market in Germany – Drivers and Barriers, 2012–2022

Table 111: Sales Forecasts ($) for Parkinson’s Disease in Italy, 2012–2022

Table 112: Key Events Impacting Sales for Parkinson’s Disease in Italy, 2012–2022

Table 113: Parkinson’s Disease Market in Italy – Drivers and Barriers, 2012–2022

Table 114: Sales Forecasts ($m) for Parkinson’s Disease in Spain, 2012–2022

Table 115: Key Events Impacting Sales for Parkinson’s Disease in Spain, 2012–2022

Table 116: Parkinson’s Disease Market in Spain – Drivers and Barriers, 2012–2022

Table 117: Sales Forecasts ($m) for Parkinson’s Disease in the UK, 2012–2022

Table 118: Key Events Impacting Sales for Parkinson’s Disease in the UK, 2012–2022

Table 119: Parkinson’s Disease Market in the UK – Drivers and Barriers, 2012–2022

Table 120: Sales Forecasts ($m) for Parkinson’s Disease in Japan, 2012–2022

Table 121: Key Events Impacting Sales for Parkinson’s Disease in Japan, 2012–2022

Table 122: Parkinson’s Disease Market in Japan – Drivers and Barriers, 2012–2022

Table 123: Sales Forecasts ($m) for Parkinson’s Disease in Brazil, 2012–2022

Table 124: Key Events Impacting Sales for Parkinson’s Disease in Brazil, 2012-2022

Table 125: Parkinson’s Disease Market in Brazil – Drivers and Barriers, 2012–2022

Table 126: Key Launch Dates

Table 127: Key Patent Expiries

List of Figures

Figure 1: 8MM, Age-Adjusted Mortality Rate of Parkinson’s Disease, Both Sexes, N, 2011

Figure 2: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, Ages =65 Years, Both Sexes, N, Select Years, 2012–2022

Figure 3: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Age, N, 2012

Figure 4: 8MM, Diagnosed Prevalent Cases of Parkinson’s Disease, by Sex, N, 2012

Figure 5: 8MM, Age-Standardized Prevalence (%) of Parkinson’s Disease, 2012

Figure 6: Overview – L-dopa Metabolism and Inhibitor Classes

Figure 7: Overview – Treatment of Motor Symptoms of Parkinson’s Disease

Figure 8: Pharmacokinetics of Levodopa

Figure 9: Clinical Trials for Parkinson’s Disease by Class and Therapeutic Strategy, 2014

Figure 10: Parkinson’s Disease – Phase II–III Pipeline, Segmented by Indication, 2014

Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson’s Disease, 2012–2022

Figure 12: Company Portfolio Gap Analysis in Parkinson’s Motor Symptoms, 2012–2022

Figure 13: Global Sales for Parkinson’s Disease by Country, 2012–2022

Figure 14: Sales for Parkinson’s Disease in the US by Drug Class, 2012–2022

Figure 15: Sales for Parkinson’s Disease in France by Drug Class, 2012–2022

Figure 16: Sales for Parkinson’s Disease in Germany by Drug Class, 2012–2022

Figure 17: Sales for Parkinson’s Disease in Italy by Drug Class, 2012–2022

Figure 18: Sales for Parkinson’s Disease in Spain by Drug Class, 2012–2022

Figure 19: Sales for Parkinson’s Disease in the UK by Drug Class, 2012–2022

Figure 20: Sales for Parkinson’s Disease in Japan by Drug Class, 2012–2022

Figure 21: Sales for Parkinson’s Disease in Brazil by Drug Class, 2012–2022

$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Central Nervous System
New
Diabetic Foot Ulcers Treatment Market Size, Share and Trends Analysis…
$3,950 | November 2022
Central Nervous System
New
Dry Eye Syndrome Market Size, Share and Trends Analysis by…
$3,950 | November 2022
Central Nervous System
New
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical…
$3,495 | November 2022